🇺🇸 FDA
Pipeline program

Abrocitinib Placebo, Abrocitinib

B7451023

Phase 3 small_molecule active

Quick answer

Abrocitinib Placebo, Abrocitinib for Moderate-to-Severe Atopic Dermatitis is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Pfizer Ireland Pharmaceuticals Unlimited Company
Indication
Moderate-to-Severe Atopic Dermatitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials